F.D.A. Delays Action on Closely Watched Alzheimer’s Drug


Pam Belluck
3/8/2024

Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy....

Original

Tags: action | agency | drug | expected | experts | independent | month



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top